February 4, 2026 — Leads & Copy — Immunome, Inc. (Nasdaq: IMNM) will present at Guggenheim’s Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET, the company announced today.
Immunome management will present at the summit.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies.
Immunome’s pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. The company is also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Source: Immunome, Inc.
